The European Society for Organ Transplantation(ESOT)has created a consensus platform for evidence-based and best-practice recommendations.At the 2022 ESOT consensus conference,nine topics were chosen for further explo...The European Society for Organ Transplantation(ESOT)has created a consensus platform for evidence-based and best-practice recommendations.At the 2022 ESOT consensus conference,nine topics were chosen for further exploration based on their potential for impact on healthcare,existing research gaps,and incomplete coverage of the topic in current scientific literature(1).Among these topics,molecular biology testing for non-invasive diagnosis of allograft rejection was a focal point,as detailed in the ESOT consensus statement on biomarkers in liver transplantation(LT)(2).We extend our congratulations to the authors of the liver subgroup on their dedicated effort and rigorous approach in translating major unmet clinical needs into four well-defined questions of interest regarding biomarkers for prediction and/or diagnosis of longer-term complications after LT.展开更多
文摘The European Society for Organ Transplantation(ESOT)has created a consensus platform for evidence-based and best-practice recommendations.At the 2022 ESOT consensus conference,nine topics were chosen for further exploration based on their potential for impact on healthcare,existing research gaps,and incomplete coverage of the topic in current scientific literature(1).Among these topics,molecular biology testing for non-invasive diagnosis of allograft rejection was a focal point,as detailed in the ESOT consensus statement on biomarkers in liver transplantation(LT)(2).We extend our congratulations to the authors of the liver subgroup on their dedicated effort and rigorous approach in translating major unmet clinical needs into four well-defined questions of interest regarding biomarkers for prediction and/or diagnosis of longer-term complications after LT.
